In contrast, the effects of FFAR2 on GLP-1 and PYY levels shed light on the therapeutic value of FFAR2 pharmacological targeting for diabetes, obesity, and other metabolic disorders. This evidence concerns the gene FFAR2 and obesity due to melanocortin 4 receptor deficiency.